MP43-08 VENOUS THROMBOEMBOLISM RISK IN TESTOSTERONE TREATED MEN WITH AND WITHOUT KLINEFELTER SYNDROME
Notice bibliographique
Résumé
You have accessJournal of UrologyCME1 Apr 2023MP43-08 VENOUS THROMBOEMBOLISM RISK IN TESTOSTERONE TREATED MEN WITH AND WITHOUT KLINEFELTER SYNDROME Christopher Lau, Yunzhe Zhang, Bethany Gabriel, Jesufikunayomi Ifeoluwa, and Tet Yap Christopher LauChristopher Lau More articles by this author , Yunzhe ZhangYunzhe Zhang More articles by this author , Bethany GabrielBethany Gabriel More articles by this author , Jesufikunayomi IfeoluwaJesufikunayomi Ifeoluwa More articles by this author , and Tet YapTet Yap More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003289.08AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: There is a higher risk of VTE in Klinefelter syndrome (KS) (∼17%) compared to the general population (∼0.1%). The risk of venous thromboembolism (VTE) as an adverse effect of testosterone therapy (TT) has been hypothesised, however there is limited data on this. TT is a common treatment for symptom management in KS, and is potentially a factor in higher VTE rates seen in KS. This study aims to evaluate the association between TT in both men with and without KS and VTE. METHODS: A literature review was performed following PRISMA guidelines, using sites such as BMJ, PubMed and ScienceDirect. Study searches, selection, data collection and analysis were carried out by four researchers independently and cross reviewed. 27 studies were selected and results from 6, which were specific to TT and VTE, were included [Table 1]. Significance level was set at p≤0.05. To assess risk of bias, tools such as Newcastle-Ottawa scale were used, and heterogeneity was found. RESULTS: The incidence of VTE in non-KS on TT ranged from 0.6-5.6% (n=2224). The incidence of VTE in KS on TT ranged from 31.3-40.0% (n=135). The background risk was 0.12% and 17.0% for the non-KS and KS groups respectively. Overall, there was a statistically significant increase in incidence of VTE in men taking TT both in the KS [χ2 = 9.95, p<.05] and non-KS [χ2 = 545.66, p<.05] patient groups. However, no statistically significant difference in VTE between the different routes of administration of TT in both the KS [χ2 = 0.12, p=.729485] and non-KS [χ2 = 7.29, p=.06309] patient groups. CONCLUSIONS: Overall, a significant increase in incidence of VTE was observed in men taking TT both in the KS and non-KS patient groups. However, similar rates of VTE between the different routes of administration of TT. Owing to the highly variable follow up period of testosterone treated men, a transient increase in risk of VTE in the first 6 months of initiating treatment was observed by a case control study. It is possible that this change was also observed in the results and therefore more data would be required exploring the long term use of TT and VTE risk. Source of Funding: N/A © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e604 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Christopher Lau More articles by this author Yunzhe Zhang More articles by this author Bethany Gabriel More articles by this author Jesufikunayomi Ifeoluwa More articles by this author Tet Yap More articles by this author Expand All Advertisement PDF downloadLoading ...
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,000 | 0,002 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,001 |
| Bibliométrie | 0,001 | 0,001 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,001 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,001 | 0,001 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,009 | 0,001 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».